0.8179

7.60% 0.0578

After Hours: .81 -0.0079 -0.97%

Geovax Labs Inc (GOVX)

Overview News Price History Financials Discussions Forecast Stock Split

Geovax Labs Inc stock is traded at $0.8179, with a volume of 145.35K. It is up +7.60% in the last 24 hours and down -37.56% over the past month. Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Previous Close:

$0.7601

Open:

$0.8

24h Volume:

145.35K

Relative Volume:

0.27

Market Cap:

$8.62M

Revenue:

$356.60K

Net Income/Loss:

$-24.32M

P/E Ratio:

-0.0885

EPS:

-9.24

Net Cash Flow:

$-27.24M

1W Performance:

-3.84%

1M Performance:

-37.56%

6M Performance:

-60.30%

1Y Performance:

-47.23%

1-Day Range:

$0.80

$0.8372

1-Week Range:

$0.745

$0.9585

52-Week Range:

$0.73

$11.18

Geovax Labs Inc Stock (GOVX) Company Profile

Name

Geovax Labs Inc

Sector

Healthcare (1153)

Industry

Biotechnology (665)

Phone

678-384-7220

Address

1900 LAKE PARK DRIVE, SMYRNA

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

GOVX's Discussions on Twitter

Compare GOVX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GOVX Geovax Labs Inc	0.8179	8.62M	356.60K	-24.32M	-27.24M	-9.24
VRTX Vertex Pharmaceuticals Inc	490.47	128.67B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	585.49	60.99B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	599.87	36.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	236.75	29.89B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	252.77	25.74B	3.81B	-644.79M	-669.77M	-6.24

Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-15-25	Reiterated	Alliance Global Partners	Buy
Apr-15-25	Reiterated	D. Boral Capital	Buy
Nov-11-24	Initiated	Alliance Global Partners	Buy
Jul-16-24	Initiated	ROTH MKM	Buy
Nov-19-20	Initiated	Maxim Group	Buy

Geovax Labs Inc Stock (GOVX) Latest News

09:00 AM

GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations - The Globe and Mail

09:00 AM

Apr 20, 2025

Analysts Issue Forecasts for GeoVax Labs FY2029 Earnings - Defense World

Apr 20, 2025

Apr 19, 2025

HC Wainwright Estimates GeoVax Labs FY2025 Earnings - Defense World

Apr 19, 2025

Apr 18, 2025

Alliance Global Partners Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $8.50 - Defense World

Apr 18, 2025

HC Wainwright Reiterates Buy Rating for GeoVax Labs (NASDAQ:GOVX) - Defense World

Apr 18, 2025

Q2 EPS Estimates for GeoVax Labs Lowered by Noble Financial - Defense World

Apr 18, 2025

Apr 16, 2025

GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates - Yahoo Finance

Apr 16, 2025

GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital - Yahoo Finance

Apr 16, 2025

GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum - Yahoo Finance

Apr 16, 2025

Apr 15, 2025

Geovax Labs stock hits 52-week low at $0.78 amid market challenges By Investing.com - Investing.com South Africa

Apr 15, 2025

Top Midday Decliners - marketscreener.com

Apr 15, 2025

These Numbers Reveal How Powerful Geovax Labs Inc (NASDAQ: GOVX) Stock Is - stocksregister.com

Apr 15, 2025

GeoVax Labs (GOVX) Faces Setback with Price Target Reduced by Ro - GuruFocus

Apr 15, 2025

GeoVax to Present at the Emerging Growth Conference on April 16, 2025 - Yahoo Finance

Apr 15, 2025

GeoVax (GOVX) Faces Setback with Termination of COVID-19 Vaccine Project | GOVX Stock News - GuruFocus

Apr 15, 2025

GeoVax's COVID-19 Vaccine Study Ended by Funding Agency; Shares Fall - marketscreener.com

Apr 15, 2025

GeoVax Labs (GOVX) Faces Setback as BARDA-Funded Trial Ends | GO - GuruFocus

Apr 15, 2025

Geovax Labs stock hits 52-week low at $0.78 amid market challenges - Investing.com Canada

Apr 15, 2025

GeoVax to Present Clinical Data at Upcoming April Industry Events - Yahoo Finance

Apr 15, 2025

GeoVax Labs (GOVX): Price Target Lowered Amid BARDA Project Pause | GOVX Stock News - GuruFocus

Apr 15, 2025

GeoVax to Discuss COVID-19 Vaccine Program and BARDA Contract at Emerging Growth Conference - citybuzz -

Apr 15, 2025

Apr 14, 2025

GeoVax Labs contract with BARDA terminated By Investing.com - Investing.com South Africa

Apr 14, 2025

GeoVax Labs Got Written Notification From Advanced Technology International - MarketScreener

Apr 14, 2025

GeoVax tumbles as HHS ends mid-stage COVID vaccine trial - TradingView

Apr 14, 2025

GeoVax Labs contract with BARDA terminated - Investing.com

Apr 14, 2025

Apr 12, 2025

Geovax labs director John Spencer buys $9,800 in stock - Investing.com Australia

Apr 12, 2025

GeoVax Labs (NASDAQ:GOVX) Earns “Buy” Rating from D. Boral Capital - Defense World

Apr 12, 2025

Apr 11, 2025

Geovax labs director John Spencer buys $9,800 in stock By Investing.com - Investing.com Canada

Apr 11, 2025

Apr 10, 2025

Geovax labs VP John Sharkey acquires $5,940 in common stock By Investing.com - Investing.com Canada

Apr 10, 2025

GeoVax Labs (GOVX) Gains Favor with BARDA Contract Amid FDA Vacc - GuruFocus

Apr 10, 2025

Geovax labs VP John Sharkey acquires $5,940 in common stock - Investing.com Australia

Apr 10, 2025

GeoVax Labs, Inc. (NASDAQ:GOVX) Given Average Recommendation of “Buy” by Analysts - Defense World

Apr 10, 2025

Apr 09, 2025

GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent - Yahoo Finance

Apr 09, 2025

Apr 07, 2025

Geovax Labs stock hits 52-week low at $0.95 amid challenges - Investing.com Australia

Apr 07, 2025

Apr 02, 2025

Short Interest in GeoVax Labs, Inc. (NASDAQ:GOVX) Drops By 12.3% - Defense World

Apr 02, 2025

Apr 01, 2025

GeoVax Labs CEO Makes Bold Stock Purchase! - TipRanks

Apr 01, 2025

Geovax labs CEO David Dodd acquires $10,800 in common stock By Investing.com - Investing.com South Africa

Apr 01, 2025

Geovax labs CEO David Dodd acquires $10,800 in common stock - Investing.com

Apr 01, 2025

Mar 31, 2025

Geovax Labs stock hits 52-week low at $1.09 amid market challenges - Investing.com

Mar 31, 2025

Roth Capital Forecasts GeoVax Labs FY2029 Earnings - Defense World

Mar 31, 2025

Mar 30, 2025

GeoVax Labs (NASDAQ:GOVX) Earns Buy Rating from D. Boral Capital - Defense World

Mar 30, 2025

Mar 29, 2025

GeoVax Labs Advances Vaccine Trials and Expands Operations - TipRanks

Mar 29, 2025

Mar 28, 2025

GeoVax Labs Earnings Call: Mixed Sentiments and Strategic Plans - TipRanks

Mar 28, 2025

GeoVax Reports 2024 Year-End Financial Results and Provides Business Update - TradingView

Mar 28, 2025

Earnings call transcript: GeoVax Q4 2024 highlights ongoing challenges By Investing.com - Investing.com Canada

Mar 28, 2025